PLoS ONE · 2012 · 88 citations · 27 references
Public HealthInfectious DiseasesDiagnostic MicrobiologyEarly DetectionTuberculosis ControlMycobacterial DiagnosticsTuberculosis CareTuberculosis DiagnosisTuberculosis Diagnostic TestingTuberculosis EpidemiologyTuberculosis Infection ControlDiagnostic Accuracy StudiesDiagnostic Testing AccuracyHiv PrevalencePatient Outcomes MeasurementStudy PhaseTuberculosis Case ManagementTuberculosis DiagnosticsTuberculosis Screening
RATIONALE: The clinical impact of Xpert MTB/RIF for tuberculosis (TB) diagnosis in high HIV-prevalence settings is unknown. OBJECTIVE: To determine the diagnostic accuracy and impact of Xpert MTB/RIF among high-risk TB suspects. METHODS: WE PROSPECTIVELY ENROLLED CONSECUTIVE, HOSPITALIZED, UGANDAN TB SUSPECTS IN TWO PHASES: baseline phase in which Xpert MTB/RIF results were not reported to clinicians and an implementation phase in which results were reported. We determined the diagnostic accuracy of Xpert MTB/RIF in reference to culture (solid and liquid) and compared patient outcomes by study phase. RESULTS: 477 patients were included (baseline phase 287, implementation phase 190). Xpert MTB/RIF had high sensitivity (187/237, 79%, 95% CI: 73-84%) and specificity (190/199, 96%, 95% CI: 92-98%) for culture-positive TB overall, but sensitivity was lower (34/81, 42%, 95% CI: 31-54%) among smear-negative TB cases. Xpert MTB/RIF reduced median days-to-TB detection for all TB cases (1 [IQR 0-26] vs. 0 [IQR 0-1], p<0.001), and for smear-negative TB (35 [IQR 22-55] vs. 22 [IQR 0-33], p=0.001). However, median days-to-TB treatment was similar for all TB cases (1 [IQR 0-5] vs. 0 [IQR 0-2], p=0.06) and for smear-negative TB (7 [IQR 3-53] vs. 6 [IQR 1-61], p=0.78). Two-month mortality was also similar between study phases among 252 TB cases (17% vs. 14%, difference +3%, 95% CI: -21% to +27%, p=0.80), and among 87 smear-negative TB cases (28% vs. 22%, difference +6%, 95% CI: -34 to +46%, p=0.77). CONCLUSIONS: Xpert MTB/RIF facilitated more accurate and earlier TB diagnosis, leading to a higher proportion of TB suspects with a confirmed TB diagnosis prior to hospital discharge in a high HIV/low MDR TB prevalence setting. However, our study did not detect a decrease in two-month mortality following implementation of Xpert MTB/RIF possibly because of insufficient powering, differences in empiric TB treatment rates, and disease severity between study phases.
27
Rapid Molecular Detection of Tuberculosis and Rifampin Resistance
Catharina Boehme, Pamela Nabeta, Doris Hillemann et al. · New England Journal of Medicine · 2010 · 2.3K citations · Full text
Catharina Boehme, Mark P. Nicol, Pamela Nabeta et al. · The Lancet · 2011 · 1K citations · Full text
Public Health, Internal Medicine, Diagnostic Microbiology +16
Danica Helb, Martin Jones, Elizabeth Story‐Roller et al. · Journal of Clinical Microbiology · 2009 · 920 citations · Full text